Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep;13(9):649-53.
doi: 10.1111/j.1751-7176.2011.00515.x. Epub 2011 Aug 8.

β-Adrenergic blockers

Affiliations
Review

β-Adrenergic blockers

William H Frishman et al. J Clin Hypertens (Greenwich). 2011 Sep.

Abstract

KEY POINTS AND PRACTICAL RECOMMENDATIONS: • β-Blockers are appropriate treatment for patients with hypertension and those who have concomitant ischemic heart disease, heart failure, obstructive cardiomyopathy, or certain arrhythmias. • β-Blockers can be used in combination with other antihypertensive drugs to achieve maximal blood pressure control. Labetalol can be used in hypertensive emergencies and urgencies. • β-Blockers may be useful in patients having hyperkinetic circulation (palpitations, tachycardia, hypertension, and anxiety), migraine headache, and essential tremor. • β-Blockers are highly heterogeneous with respect to various pharmacologic effects: degree of intrinsic sympathomimetic activity, membrane-stabilizing activity, β(1) selectivity, α(1) -adrenergic-blocking effect, tissue solubility, routes of systemic elimination, potencies and duration of action, and specific effects may be important in the selection of a drug for clinical use. • β-Blocker usage to reduce perioperative ischemia and cardiovascular complications may not benefit as many patients as was once hoped and may actually cause harm in some individuals. Currently the best evidence supports β-blocker use in two patient groups: patients undergoing vascular surgery with known ischemic heart disease or multiple risk factors for it and for patients already receiving β-blockers for known cardiovascular conditions.

PubMed Disclaimer

References

    1. Prichard BNC. Hypotensive action of pronethalol. Br Med J. 1964;1:1227–1228. - PMC - PubMed
    1. Prichard BNC, Gillam PMS. Use of propranolol (Inderal) in the treatment of hypertension. Br Med J. 1964;2:725–727. - PMC - PubMed
    1. Frishman WH. Alpha‐and beta‐adrenergic blocking drugs. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd ed. Minneapolis, MN: Cardiotext Inc.; 2011:57–86.
    1. Frishman WH, Sica DA. β‐Adrenergic blockers. In: Izzo JL Jr, Sica D, Black HR, eds. Hypertension Primer, 4th ed.: The Essentials of High Blood Pressure. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:446–450.
    1. Mansoor GA, Frishman WH. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis. 2002;4:358–371. - PubMed

MeSH terms

Substances